La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Paysign Crescita futura

Future criteri di controllo 1/6

Si prevede che gli utili di Paysign diminuiranno del 29.1% all'anno, mentre si prevede che il fatturato annuo crescerà del 13.5% all'anno. Si prevede che l'EPS diminuirà del 34.3% all'anno.

Informazioni chiave

-29.1%

Tasso di crescita degli utili

-34.3%

Tasso di crescita dell'EPS

Diversified Financial crescita degli utili	1.2%
Tasso di crescita dei ricavi	13.5%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	06 Aug 2024

Aggiornamenti recenti sulla crescita futura

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02

Recent updates

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02

Paysign: Expect Rapid Growth In Its Pharma Business

Jun 30

Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Apr 26

Earnings Update: Here's Why Analysts Just Lifted Their PaySign, Inc. (NASDAQ:PAYS) Price Target To US$3.75

Aug 13

Calculating The Fair Value Of PaySign, Inc. (NASDAQ:PAYS)

Jun 14

At US$1.42, Is PaySign, Inc. (NASDAQ:PAYS) Worth Looking At Closely?

May 16

PaySign: A 'Backdoor' $2 Stagflation Play

Mar 29

Paysign: My Top Rebound Pick For 2022

Dec 28

Paysign: The Plasma Toll Booth

Sep 23

PaySign's Post-Pandemic Payoff

Sep 07

Why PaySign Is A Very Good Company

Dec 28

PaySign: Long-Term Story Still Intact

Dec 21

Paysign reports Q3 results

Nov 17

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:PAYS - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	66	5	N/A	N/A	4
12/31/2024	58	3	N/A	N/A	4
6/30/2024	54	8	48	56	N/A
3/31/2024	50	7	25	33	N/A
12/31/2023	47	6	21	28	N/A
9/30/2023	44	2	-8	-1	N/A
6/30/2023	42	1	4	9	N/A
3/31/2023	40	1	18	23	N/A
12/31/2022	38	1	21	25	N/A
9/30/2022	36	0	27	30	N/A
6/30/2022	33	-1	11	14	N/A
3/31/2022	31	-1	8	10	N/A
12/31/2021	29	-3	13	15	N/A
9/30/2021	28	-7	14	17	N/A
6/30/2021	20	-13	25	27	N/A
3/31/2021	20	-12	10	13	N/A
12/31/2020	24	-9	10	14	N/A
9/30/2020	27	-3	14	18	N/A
6/30/2020	36	6	-2	3	N/A
3/31/2020	38	8	3	7	N/A
12/31/2019	35	7	13	17	N/A
9/30/2019	32	6	16	18	N/A
6/30/2019	29	4	27	29	N/A
3/31/2019	26	3	33	34	N/A
12/31/2018	23	3	14	16	N/A
9/30/2018	21	2	10	12	N/A
6/30/2018	19	2	8	10	N/A
3/31/2018	17	2	N/A	7	N/A
12/31/2017	15	2	N/A	7	N/A
9/30/2017	14	2	N/A	6	N/A
6/30/2017	12	2	N/A	3	N/A
3/31/2017	11	2	N/A	5	N/A
12/31/2016	10	1	N/A	4	N/A
9/30/2016	10	1	N/A	1	N/A
6/30/2016	9	-2	N/A	3	N/A
3/31/2016	9	-2	N/A	0	N/A
12/31/2015	8	-2	N/A	-1	N/A
9/30/2015	11	0	N/A	3	N/A
6/30/2015	11	3	N/A	3	N/A
3/31/2015	9	2	N/A	2	N/A
12/31/2014	10	3	N/A	3	N/A
9/30/2014	7	0	N/A	1	N/A
6/30/2014	7	0	N/A	0	N/A
3/31/2014	7	0	N/A	0	N/A
12/31/2013	6	1	N/A	-1	N/A
9/30/2013	6	0	N/A	0	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che gli utili di PAYS diminuiranno nei prossimi 3 anni ( -29.1% all'anno).

Guadagni vs Mercato: Si prevede che gli utili di PAYS diminuiranno nei prossimi 3 anni ( -29.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di PAYS diminuiranno nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di PAYS ( 13.5% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di PAYS ( 13.5% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di PAYS è previsto essere elevato tra 3 anni

Paysign Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 22%, revenue upgraded

Price target increased by 7.5% to US$6.58

Paysign, Inc. Revises Earnings Guidance for the Full Year 2024

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Paysign, Inc. Revises Earnings Guidance for the Full Year 2024

Consensus EPS estimates increase by 33%

Recent updates

New minor risk - Insider selling

Consensus EPS estimates fall by 22%, revenue upgraded

Price target increased by 7.5% to US$6.58

Paysign, Inc. Revises Earnings Guidance for the Full Year 2024

Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Paysign, Inc. Revises Earnings Guidance for the Full Year 2024

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improves as stock rises 34%

Paysign: Expect Rapid Growth In Its Pharma Business

Independent Director exercised options to buy US$85k worth of stock.

Consensus EPS estimates increase by 33%

Price target increased by 8.9% to US$6.13

First quarter 2024 earnings released: EPS: US$0.006 (vs US$0.003 loss in 1Q 2023)

Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

New minor risk - Share price stability

Investor sentiment improves as stock rises 26%

Consensus EPS estimates fall by 30%, revenue upgraded

PaySign, Inc., Annual General Meeting, May 03, 2024

Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching

Price target increased by 14% to US$5.25

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CFO & Treasurer exercised options and sold US$79k worth of stock

PaySign, Inc. Announces Executive Changes

Revenues Tell The Story For PaySign, Inc. (NASDAQ:PAYS)

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of the Common Stock of Paysign, Inc

Consensus EPS estimates increase by 25%

New major risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Market cap size

Consensus EPS estimates fall by 50%

PaySign, Inc. Reaffirms Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0.004 loss in 2Q 2022)

Co-Founder exercised options and sold US$71k worth of stock

New minor risk - Market cap size

Consensus EPS estimates fall by 20%

First quarter 2023 earnings released: US$0.003 loss per share (vs US$0.006 loss in 1Q 2022)

Consensus EPS estimates increase by 36%

Price target increased by 13% to US$4.31

CFO & Treasurer recently sold US$101k worth of stock

PaySign, Inc. Elects Jeffrey B. Newman to Its Board of Directors

Consensus EPS estimates have been upgraded.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

PaySign, Inc. Provides Earnings Guidance for the Fiscal Year 2022

General Counsel exercised options to buy US$54k worth of stock.

The Recovery At PaySign Has Legs

Earnings Update: Here's Why Analysts Just Lifted Their PaySign, Inc. (NASDAQ:PAYS) Price Target To US$3.75

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$3.75

PaySign, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2022

Calculating The Fair Value Of PaySign, Inc. (NASDAQ:PAYS)

At US$1.42, Is PaySign, Inc. (NASDAQ:PAYS) Worth Looking At Closely?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

PaySign, Inc. Provides Earnings Guidance for the Full Year of 2022

PaySign, Inc. Provides Earnings Guidance for the Full Year of 2022

Price target decreased to US$3.44

Insufficient new directors

Price target decreased to US$3.44

Insufficient new directors

PaySign: A 'Backdoor' $2 Stagflation Play

Paysign: My Top Rebound Pick For 2022

Paysign: The Plasma Toll Booth

PaySign's Post-Pandemic Payoff

PaySign, Inc.(NasdaqCM:PAYS) dropped from Russell 2000 Defensive Index

PaySign, Inc. Provides Earnings Guidance for the Full Year 2021

Paysign, Inc. Announces Retirement of Joan M. Herman, as Chief Operating Officer

Why PaySign Is A Very Good Company

PaySign: Long-Term Story Still Intact

PaySign, Inc. and ImmunoTek Bio Centers LLC Collaborate in Support of COVID-19 Convalescent Plasma Collection

PaySign, Inc. announced delayed 10-Q filing